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Summary Congenital erythropoietic porphyria (CEP) is a rare autosomal recessive disease owing to the
deficient activity of uroporphyrinogen III synthase, the fourth enzyme in the porphyrin–haem
synthetic pathway. Of the porphyrias, it is the most mutilating type, usually presenting early in life.
To date, 12 documented cases of adult onset CEP have been reported. We report the second oldest
documented patient with late onset CEP with incidental findings of thrombocytopenia and
myelodysplasia with bone-marrow sideroblasts. We further discuss several current and future
treatment options for this therapeutically challenging disease.
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Congenital erythropoietic porphyria (CEP), or Gün-
ther’s disease, is an autosomal recessively inherited
disorder resulting from a variably deficient, but not
absent, activity of uroporphyrinogen III synthase, the
fourth enzyme in the porphyrin–haem synthetic path-
way. It is a rare disease with approximately 130 cases
reported to date.1 The disease usually manifests in the
first decade of life, with only 12 reported cases
beginning in adulthood.2–11 We report the second
oldest documented patient of late onset CEP.
Case report
A 72-year-old caucasian male was referred to the
Department of Dermatology at Henry Ford Hospital in
June 2001 for severe blistering and skin fragility. His
skin had been completely normal until September
2000 when he developed two vesicles that later crusted
on the left index finger after playing golf. These lesions
resolved during the winter months, only to recur when
he travelled to Florida in February 2001. His cutaneous
manifestations progressively worsened with the devel-
opment of erythema, oedema, skin fragility, vesicles,
crusted erosions and scarring on the sun-exposed areas
of his hands, forearms, neck, face and scalp (Fig. 1).
This was associated with pruritus, paraesthesia and
pain. The colour of both the vesicular fluid and urine
were a distinctive rusty-red. Hypertrichosis and eryth-
rodontia were not present. He consumed an average of
one alcoholic beverage per week.
Prior to our consultation, the patient underwent two
phlebotomies for treatment of suspected porphyria
cutanea tarda. Subsequently, full blood count revealed
thrombocytopenia and normochromic macrocytic
anaemia [haemoglobin: 10Æ4 g dL)1 (13Æ5–17Æ0);
MCV: 111Æ2 fl (80–100); MCHC: 33Æ5 g dL)1 (31–
37); platelet count: 74 · 109 L)1 (150–450)]. Iron
studies were within normal limits [iron: 125 lg dL)1
(60–140); total iron binding: 317 lg dL)1 (250–425);
iron saturation: 39% (15–50)]. A bone marrow
aspirate analysis revealed erythroid hyperplasia and
severe dyserythropoiesis suggestive of myelodys-
plastic syndrome; in addition, ringed sideroblasts were
observed. A shave biopsy of a vesicle performed by the
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referring dermatologist showed bullous changes within
the corneal layer consistent with spongiotic dermatitis.
The patient’s past medical history was significant for
a splenectomy performed in the mid-1970s for a
lacerated spleen secondary to trauma. Perioperatively,
he required multiple transfusions. Hepatitis C antibod-
ies were incidentally detected with a normal liver
profile during a sepsis work-up after a coronary artery
bypass graft procedure in 1993. He also had a history
of prostate carcinoma, for which the patient underwent
total prostatectomy.
Following the consultation, analysis of the patient’s
porphyrin profile at the University of Texas Medical
Branch (Galveston, TX, U.S.A.) revealed elevated total
plasma, urine, erythrocyte and fecal porphyrins
(Table 1). Maximum plasma fluorescence at neutral
pH was 617 nm, which could be observed in CEP. In
plasma, urine and erythrocytes, the predominant
porphyrins were uroporphyrin and coproporphyrin.
In all specimens, isomer I predominated. Urine d-ami-
nolevulinic acid and porphobilinogen, and erythrocyte
uroporphyrinogen decarboxylase levels were within
normal limits. Altogether, these findings were consis-
tent with CEP. With this diagnosis, cytogenetic analysis
was pursued. As our institution does not perform
fluorescent in situ hybridization (FISH) for CEP, stand-
ard chromosomal analysis was done revealing a
normal male karyotype (46, XY) without evidence of
chromosomal breakage or deletion.
Preventative and symptomatic measures constitute
the patient’s current treatment. Maximal avoidance of
sun-exposure is performed daily by the patient, with
the use of photoprotective clothing (Solumbra),
broad-brimmed hat, gloves and a sunscreen of SPF
35 containing zinc oxide and cinnamate. An oral beta
carotene (Lumitene 180 mg day)1) and an oral
antipruritic agent have also been administered. These
resulted in a moderate decrease in cutaneous symp-
toms.
Discussion
The first case of CEP was described by Schultz in 1874,1
and later described in detail by Günther in 1911.1 It is
the most mutilating type of the porphyrias presenting
with moderate to severe cutaneous photosensitivity.
CEP is due to deficient activity of uroporphyrinogen III
synthase. Patients have normal levels of immunoreac-
tive enzyme protein and markedly reduced enzyme
activity (£ 15% normal).12 This results in the pre-
dominant accumulation of uroporphyrin I and cop-
orphyrin I in all cells and tissues. The presence of these
porphyrin isomers allows for the absorption of photons
in the Soret band spectrum (400–410 nm) with minor
absorption between 500 and 700 nm. Photosensitivity
develops as a result of generation of reactive oxygen
species and inflammatory mediators, leading to tissue
damage.13
Following sun exposure, infants with CEP typically
cry because of a burning and stinging sensation with
pruritus of the exposed skin. Cutaneous findings include
marked fragility, eroded or intact vesicles and bullae
that may contain pink fluorescent fluid, hypertrichosis
of lanugo-type hair in sun-exposed areas, dyspigmen-
tation, diffuse scarring and atrophy, which may result
in deformity of the ears, nose, fingers and face, scarring
alopecia and sclerodermoid changes. Patients also have
pink-red urine that fluoresces under Wood’s light.
Associated complications include keratoconjunctivitis,
corneal scarring, scleral ulceration, cataracts, hepato-
splenomegaly, and osteolysis.13–15 Erythrodontia,
owing to deposition of porphyrins, is a common finding
Figure 1. (a) Erosions and crusting on dorsum of hands secondary
to skin fragility. (b) Blister at the lateral aspect of a finger.
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of CEP. Predominant elevation of uroporphyrin I and
coproporphyrin I in urine, and coproporphyrin I in
faeces, with normal urinary d-aminolevulinic acid and
porphobilinogen levels are found.
Including the patient described herein, there has
been a total of only 13 cases of CEP reported worldwide
with age of onset older than 18 years, with our patient
being the second oldest (Table 2). The age of onset
ranged from 23 to 74 years; only one of the 13 patients
was female. Compared to early onset CEP, patients with
late onset disease tend to have less severe manifesta-
tions presumably due to a less severe deficiency of the
uroporphyrinogen III synthase activity. Whether the
splenectomy performed in our patient 25 years prior to
the cutaneous manifestation resulted in the delayed
onset of the disease remains purely speculative at this
Table 2. Patients with late onset congenital erythropoietic porphyria*
Case Authors and ref. (year) Sex Ethnicity Age at onset (years) Thrombocytopenia Myelodysplasia
1 Kramer et al.2 (1965) M Bantu 54 +
2 Pain et al.3 (1975) M Australian 58 + +
3 MacDonald et al.4 (1978) M Greek 51 + +
4 Deybach et al.5 (1981) M French 36
5 Deybach et al.5 (1981) M Algerian 23
6 Mukerji et al.6 (1985) M White 53
7 Horiguchi et al.7 (1989) M Japanese 26
8 Horiguchi et al.7 (1989) F Japanese 36
9 Rank et al.8 (1990) M E. European 51 + +
10 Yamauchi and Kushibiki9 (1992) M Japanese 63 + +
11 Murphy et al.10 (1995) M Caucasian 65 + +
12 Ibbotson et al.11 (1998) M NR 74 + +
13 Kontos et al. (this paper) M German ⁄ French 72 + +
*Modified from Fritsch et al.1 NR, not reported.
Table 1. Porphyrin profile of the patient
Specimen Test Value (normal range)*
Plasma Total porphyrins 42Æ9 lg dL)1L (0–0Æ9)
Uroporphyrin 9Æ9 lg dL)1
Heptacarboxyl porphyrin 10Æ7 lg dL)1
Hexacarboxyl porphyrin 0Æ9 lg dL)1L
Pentacarboxyl porphyrin 6Æ4 lg dL)1
Coproporphyrin 14Æ6 lg dL)1
Maximum fluorescence at neutral pH 617 nm
Urine (3500 mL 24 h)1) Total porphyrins 24 160 nmol 24 h)1 (0–300)
Uroporphyrin 59% (0–30% of total)
Heptacarboxyl porphyrin 1% (0–5% of total)
Hexacarboxyl porphyrin 1% (0–5% of total)
Pentacarboxyl porphyrin 5% (0–5% of total)
Coproporphyrin 34% (50–100% of total)
d-Aminolevulinic acid 2Æ8 mg 24 h)1 (0–7)
Porphobilinogen 1Æ3 mg 24 h)1 (0–4)
Erythrocytes Total porphyrins 695 lg dL)1 (20–80)
Uroporphyrin 327 lg dL)1
Heptacarboxyl porphyrin 21 lg dL)1
Hexacarboxyl porphyrin 7 lg dL)1
Pentacarboxyl porphyrin 28 lg dL)1
Coproporphyrin 306 lg dL)1
Uroporphyrinogen decarboxylase 59Æ3 nmol mL RBC)1 h)1 (35–60)
Faeces Total porphyrins 3050 nmol g)1 dry weight (0–200)
Pentacarboxyl porphyrin 1% (0–10% of total)
Coproporphyrin 98% (30–100% of total)
*All porphyrins are predominantly isomer I by high performance liquid chromatography.
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time. Of interest, eight of the 13 patients with late onset
disease had thrombocytopenia, and seven of them had
myelodysplasia. All of the patients with myelodysplasia
were older than 50 years, while only two of the six
without myelodysplasia were older than 50 years.
Therefore, it is possible that there may be two types
of late onset CEP, one associated with myelodysplasia
with acquired mutation of the UROS gene, while the
other is caused by germ-line UROS gene mutations
with mild phenotypic expression. Ringed sideroblasts
were observed in the bone marrow of our patient. Of
interest, deletion of the ferrocheletase gene and the
presence of ringed sideroblasts as part of the myelod-
ysplastic process have been recently reported in
late onset erythropoietic protoporphyria (EPP).16 In
addition, sideroblastic anaemia, photosensitivity, and
abnormal porphyrin profile (elevated erythrocyte,
plasma and fecal protoporphyrin, and elevated urinary
coporphyrin) have been reported previously in at least
six other patients, two of whom are patients with late
onset EPP.17
At least 22 mutations responsible for CEP have been
identified in the uroporphyrinogen III synthase gene
located on chromosome 10. These include 18 point,
deletion and insertion mutations,1,12,18 and four pro-
moter mutations.19 The heterogeneity of these muta-
tions may provide a better understanding of predicting
the severity of CEP. Of all the documented mutations,
the most severe and common mutation is a single,
missense mutation designated C73R.20–22 It has been
suggested that late onset CEP may represent a hetero-
zygous state;3 however, Deybach et al.5 refute this
hypothesis based on their observations of markedly
suppressed uroporphyrinogen III synthase activity in
two patients with late onset CEP.
Treatment of CEP is very challenging. The use of
photoprotective clothing, broad-brimmed hats, and
UV-protected sunglasses should be recommended. The
only topical agents fully protective at the Soret band
range are non-micronized inorganic sunscreen agents
such as titanium dioxide and zinc oxide; however,
because of the pasty nature of the preparations, they
are not practical for daily use. Therefore, while
currently available organic and micronized inorganic
sunscreen agents do not adequately absorb the Soret
band range, they are still recommended to patients as
part of the total sun-avoidance package. Recently,
newly formulated sunscreens containing pigmentary
titanium dioxide with zinc oxide offered protection to
the UVB and UVA spectra with extended coverage
into the blue light region of the visible spectrum,
making this an exciting option for photosensitive
patients.23 Oral beta carotene at doses of 120–
180 mg day)1 have been reported to improve light
tolerance in some.1,13,24 The use of oral charcoal and
cholestyramine to interrupt the enterohepatic circula-
tion of porphyrins has been variably success-
ful.1,6,13,15,24,25 Splenectomy transiently improves
haemolytic anaemia and increases the lifespan of
erythrocytes, leading to a decrease in photosensitiv-
ity.1,13,15,22 The concomitant use of erythrocyte
transfusion and hydroxyurea has been shown to
decrease porphyrin production and excretion by
suppression of erythropoiesis in bone marrow.15,22
However, the risk of iron overload and ⁄ or acquiring
an infectious disease must be taken into consideration.
Pyridoxal 5-phosphate has been used to treat anaemia
in a patient with late onset CEP and myelodysplastic
syndrome; urinary porphyrin concentration decreased
to normal levels, but the anaemia worsened.1,9 The
use of cyclophosphamide has been implemented in a
patient with late onset CEP and nephrotic syndrome.
Erythrocyte uroporphyrin and coproporphyrin and
urinary coproporphyrin levels were reduced, with
little cutaneous photosensitivity seen 7–12 months
after cessation of therapy.26 Allogeneic stem cell
transplantation has been shown to be an effective, if
not curative, treatment option for severe CEP.15,27,28
In vitro retroviral-mediated transfer of the
uroporphyrinogen III synthase gene into cells deficient
in uroporphyrinogen III synthase has been shown to
completely restore enzymatic activity in cultured stem
cells, showing promise for ex vivo therapy for severe
CEP.15,22,29
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